Biodexa Pharmaceuticals

Company snapshot

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of treatments aimed at diseases with high unmet clinical need. The company’s lead development programme, eRapa, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is b

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Biodexa Pharmaceuticals. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Biodexa Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   MTX230-301 — Phase 3

2. Jun 8, 2026 Clinical update

   eRapa (encapsulated rapamycin) — Phase 3

3. Jun 8, 2026 Clinical update

   Encapsulated Rapamycin (eRapa) — Phase 2

4. May 23, 2026 Clinical update

   MTX110 — Phase 1

5. Sep 5, 2006 Patent grant

   Pharmaceutical compositions with wound healing or anti-complementary activity comprising a dextran derivative

View all clinical trial activity →

• What is Biodexa Pharmaceuticals?

  Biodexa Pharmaceuticals is a pharma organization headquartered in cardiff, GB. It trades on NYSE under ticker BDRX. Primary therapeutic focus areas include Familial adenomatous polyposis (FAP), Familial Adenomatous Polyposis, Familial Adenomatous Polyposis (FAP), Recurrent Gliobl

• Is Biodexa Pharmaceuticals publicly traded?

  Yes. Biodexa Pharmaceuticals is listed with ticker BDRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Biodexa Pharmaceuticals develop or market?

  We link 5 drug profile(s) where Biodexa Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/biodexa-pharmaceuticals-plc#company-drugs.

• What are the latest developments for Biodexa Pharmaceuticals?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Biodexa Pharmaceuticals focus on?

  Biodexa Pharmaceuticals focuses on Familial adenomatous polyposis (FAP), Familial Adenomatous Polyposis, Familial Adenomatous Polyposis (FAP) based on our analysis of their pipeline programs and drug development activities.